Compare VFS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VFS | PCVX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Vietnam | United States |
| Employees | 17823 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.1B |
| IPO Year | N/A | 2020 |
| Metric | VFS | PCVX |
|---|---|---|
| Price | $2.85 | $53.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $5.83 | ★ $98.33 |
| AVG Volume (30 Days) | 289.4K | ★ 1.1M |
| Earning Date | 03-16-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,810,877.80 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.56 | $28.09 |
| 52 Week High | $3.82 | $75.33 |
| Indicator | VFS | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 26.99 | 41.02 |
| Support Level | N/A | $42.30 |
| Resistance Level | $3.56 | $56.04 |
| Average True Range (ATR) | 0.08 | 2.50 |
| MACD | -0.03 | -0.85 |
| Stochastic Oscillator | 18.09 | 7.80 |
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Car, E-scooter and Ebus. The Car segment includes the design, development, manufacturing and sales of cars and related battery lease and battery charging services for cars. The E-scooter segment includes the design, development, manufacturing and sales of e-scooters and related battery lease and battery charging service for e-scooters. The Ebus segment includes the design, development, manufacturing and sales of Ebus.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.